Stocktoria
Alpha Teknova, Inc. TKNO
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2021-06-25
Alpha Teknova, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 33.2% | 19.2% | 28.1% | 42.2% | 47.8% |
| Operating margin | -41.9% | -69.3% | -96.9% | -119.9% | -32.5% |
| Net margin | -42.6% | -70.9% | -100.3% | -114.6% | -26.6% |
| FCF margin | -24.2% | -35.8% | -72.9% | -134.1% | -78.5% |
| Return on assets | -16.7% | -22.5% | -28.6% | -31.2% | -5.9% |
| Return on equity | -25.1% | -32.5% | -40.9% | -47.5% | -6.8% |
| Debt / equity | 0.19× | 0.11× | 0.15× | 0.22× | 0.08× |
| Current ratio | 4.58 | 3.82 | 5.14 | 5.62 | 13.07 |
| Revenue growth | 7.4% | 2.9% | -11.4% | 12.3% | 17.9% |
Source: SEC EDGAR filings · CIK 0001850902 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.